, said on Saturday, December 12, it was buying United States biotech firm Alexion for $39 billion to boost its work on immunology.
"We look forward to welcoming our new colleagues at Alexion so that we can together build on our combined expertise in immunology and precision medicines to drive innovation that delivers life-changing medicines for more patients," he said. Since taking the helm at AstraZeneca in 2012, Soriot has pushed the group into lucrative treatments such as cancer therapies, and the Alexion takeover will give it more heft in areas such as treating blood disorders.
On Tuesday, December 8, the UK partners became the first COVID-19 vaccine makers to publish final-stage clinical trial data in a scientific journal, clearing a key hurdle.
Source: News Formal (newsformal.com)